Review articleOxygen free radicals and Parkinson's disease
References (93)
- et al.
Monamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity
Neurosci. Lett.
(1988) - et al.
The regional distribution and cellular localization of iron in the rat brain
Neurosci.
(1984) - et al.
Increased nigral iron content in postmortem parkinsonian brain
Lancet
(1987) - et al.
Effect of ascorbic acid on neurochemical, behavioral, and physiological systems mediated by catecholamines
Life Sci.
(1979) - et al.
Lipid peroxidation as cause of nigral cell death in Parkinson's disease
Lancet
(1986) Overview of methods used for detecting lipid peroxidation
Meth. Enzymol.
(1984)- et al.
Lipid peroxidation and Parkinson's disease
Lancet
(1986) - et al.
Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease
Neurosci. Lett.
(1988) - et al.
Erythrocyte antioxidant activity in human patients with Parkinson's disease
Neurosci. Lett.
(1987) - et al.
Glutathione peroxidase activity in Parkinson's disease
Neurosci. Lett.
(1985)
Oxygen toxicity protecting enzymes in Parkinson's disease
J. Neurol. Sci.
Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
Neurosci. Lett.
Microperoxisome distribution in the central nervous system of the rat
Brain Res.
Distribution of superoxide dismutase, glutathione peroxidase and catalase in developing rat brain
Mech. Ageing Devel.
Superoxide dismutase activity in brains from chronic alcoholics
Drug Alc. Depend.
Histochemical evaluation of glutathione in brain
Brain Res.
Reduced and oxidized glutathione in human and monkey brain
Neurosci. Lett.
Parkinson's disease: a disorder due to nigral glutathione deficiency?
Neurosci. Lett.
Oxidative stress in the nervous system
Mechanism of dismutation of superoxide produced during autoxidation of melanin pigments
Biochem. Biophys. Res. Commun.
Possible role of neuromelanin in the pathogenesis of Parkinson's disease
Mech. Ageing Devel.
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Psychiatry Res.
Amyotrophic lateral sclerosis and Parkinson's disease complex on guam linked to an environmental neurotoxin
Trends Neurol. Sci.
The role of environmental toxins in the etiology of Parkinson's disease
Trends Neurol. Sci.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) and free radicals in vitro
Biochem. Pharmacol.
Formation of superoxid and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P450 reductase
Biochem. Biophys. Res. Commun.
Chemically induced parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenylpyridinium ion
Biochem. Biophys. Res. Commun.
MPTP toxicity in the mouse brain and vitamin E
Neurosci. Lett.
Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice
Biochem. Pharmacol.
Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid
Neuropharmacol.
Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs
Lancet
The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl
Mech. Ageing Devel.
New insights into the pathophysiology of Parkinson's disease: the challenge of positron emission tomography
Trends Neurol. Sci.
Extracellular increase of hypoxanthine and xanthine in the cortex and basal ganglia of fetal lambs during hypoxia-ischemia
Brain Res.
Mitochondrial complex I deficiency in Parkinson's disease
Lancet
Distribution of xanthine dehydrogenase and oxidase activities in human and rabbit tissues
Biochim. Biophys. Acta
Brain anoxia release striatal dopamine in rats
Life Sci.
Biochemical pathophysiology of Parkinson's disease
Adv. Neurol.
Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease
Eur. Neurol.
Loss of neurons in the nucleus of meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease
Acta Neuropathol.
Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders
J. Neurochem.
Neurophathology of immunohistochemically identified brainstem neurons in Parkinson's disease
Ann. Neurol.
Distinct monoamine oxidase A and B populations in primate brain
Science
Parkinson diseasem dementia and Alzheimer's disease: clinicopathological correlations
Ann. Neurol.
Pathologic correlates of dementia in Parkinson's disease
Arch. Neurol.
Lewy bodies in Alzheimer disease-one or two diseases?
Alzh. Dis. Assoc. Disorders
Cited by (298)
Neuroprotective effects of flavonoids
2023, Phytonutrients and Neurological Disorders: Therapeutic and Toxicological AspectsThe development of the concept of ferroptosis
2019, Free Radical Biology and MedicineCitation Excerpt :Thus, mechanisms of controlling ferroptotic cell death are being investigated in recent years as therapeutic means for multiple pathologies. Although there has been evidence for the involvement of lipid peroxidation and oxidative stress in numerous neurological conditions for a few decades before ferroptosis was described [184–186], brain cell death in neurological and neuropsychiatric conditions was attributed to apoptosis, and acute central nervous system (CNS) cell death events such as traumatic brain injury and infection, were considered to be due to necrosis [187]. Following the discovery of ferroptosis, this paradigm is under challenge, with ferroptosis now being suggested as the main driver of neurological cell death in diseases such as Parkinson's disease (PD) and Alzheimer disease (AD) [188–191].
Silymarin recovers 6-hydroxydopamine-induced motor deficits in mice
2018, Food and Chemical ToxicologyCitation Excerpt :The two MAO isoforms are distributed throughout all tissues, the inhibition of MAO-A can provide protection against apoptosis (Ou et al., 2006) while the inhibition of MAO-B is related a therapeutic role in the treatment of PD (Youdim and Bakhle, 2006). It has been showed that an increase in MAO-B activity is associated with increases in the production of this reactive oxygen species (ROS) (Adams and Odunze, 1991). This increase in ROS and consequently of oxidative stress contribute to a decrease in neuronal mitochondrial function, deterioration dopaminergic neuron viability, and ultimately leads to cell death and motor impairment (Koppula et al., 2012; Mallajosyula et al., 2008; Prajapati et al., 2017).
L-dopa co-drugs in nanostructured lipid carriers: A comparative study
2017, Materials Science and Engineering CFermentation enhances Ginkgo biloba protective role on gamma-irradiation induced neuroinflammatory gene expression and stress hormones in rat brain
2016, Journal of Photochemistry and Photobiology B: BiologyInhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice
2016, Hormones and BehaviorCitation Excerpt :MAO B is found in the brain astrocytes (Ekblom et al., 1993; Levitt et al., 1982) and radial glial cells (Westlund et al., 1988). It has been postulated that increases in MAO B activity may contribute to cellular degeneration in the brain (Adams and Odunze, 1991). Thus, these findings do not indicate that increased astrocyte activation and MOA-B expression could be significant in the dopaminergic degeneration in ERα KO mice; thus, ER deficiency accelerates PD-associated behaviors.
- a
James D. Adams Jr. received an AB degree from the University of California Riverside and a PhD from the University of California San Francisco. He has interests in glutathione, vitamin E, lipid peroxidation, and oxidative stress as well as Parkinson's disease. He is an assistant professor at the University of Southern California.
- b
Ifeoma N. Odunze is a graduate of the University of Ibadan, Nigeria where she received both a BS and PhD. She is currently a post-doctoral fellow at the University of Southern California.